Roth Capital Starts ImmunoCellular Therapeutics (IMUC) at Buy
Tweet
Share
E-mailGet Alerts IMUC Hot Sheet
Price: $0.16 +45.45%
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 12 | New: 74
Rating Summary:
2 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 12 | New: 74
Join SI Premium – FREE
Earlier, Roth Capital initiated coverage on ImmunoCellular Therapeutics (NYSE: IMUC) with a Buy. PT $6.00.
For an analyst ratings summary and ratings history on ImmunoCellular Therapeutics click here. For more ratings news on ImmunoCellular Therapeutics click here.
Shares of ImmunoCellular Therapeutics closed at $2.03 yesterday.
For an analyst ratings summary and ratings history on ImmunoCellular Therapeutics click here. For more ratings news on ImmunoCellular Therapeutics click here.
Shares of ImmunoCellular Therapeutics closed at $2.03 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Starts IsoEnergy (ISOU) at Outperform
- Wells Fargo Starts The Blackstone Group (BX) at Equal Weight
- Wells Fargo Starts Brookfield Asset Management (BAM) at Overweight
Create E-mail Alert Related Categories
New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
